Ángela Santana Valenciano, Luz Divina Juez Sáez, Belén Pérez Mies, Sara Corral Moreno, Sonia Rivas Fidalgo, Jacobo Cabañas Montero
{"title":"非原发性乳腺恶性肿瘤的乳腺转移:我们应该知道什么?","authors":"Ángela Santana Valenciano, Luz Divina Juez Sáez, Belén Pérez Mies, Sara Corral Moreno, Sonia Rivas Fidalgo, Jacobo Cabañas Montero","doi":"10.3233/BD-220056","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metastases from extramammary malignant neoplasms are very rare, accounting for less than 2% of all breast malignancies.</p><p><strong>Objective: </strong>The aim of this study is to describe the clinicopathological features and prognosis of breast metastases from non-primary breast malignancies at our institution.</p><p><strong>Methods: </strong>We performed a retrospective observational study, obtaining data from electronic medical records and pathology databases between January 1985 and December 2020 for patients diagnosed with breast metastasis from non-primary breast malignancies. Only patients diagnosed by biopsy were included.</p><p><strong>Results: </strong>Fifteen patients diagnosed with breast metastases from non-primary breast malignancies were included, 13 women (86,67%) and 2 men (13,33%). The median age at time of initial diagnosis was 56 years (IQR 21-68). The most frequent primary malignancy was melanoma (9/15; 60%). The median time to diagnosis of breast metastases was 65 months (IQR 13-106). The most common diagnostic modality was CT-scan (10/15; 66,67%). The median follow-up was 96 months (IQR 29-136). Eight patients underwent surgery (53,3%), being the most common surgical intervention breast-conserving surgery (5/8; 62,5%). Mortality at the end of follow-up was 53,3% (8/15). On the survival analysis, we found no differences between patients undergoing surgery and those only receiving systemic treatment [41,5 months (IQR 17,5-57,5) versus 14 months (IQR 2-24), respectively; p = 0,161].</p><p><strong>Conclusions: </strong>Breast metastases from non-primary breast malignancies are extremely rare and represent a diagnostic and therapeutic challenge, due to the poor prognosis of these patients. Thus, arriving at the correct diagnosis is crucial to avoid unnecessary treatment in this population.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"223-228"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Breast metastases from non-primary breast malignancies: What should we know?\",\"authors\":\"Ángela Santana Valenciano, Luz Divina Juez Sáez, Belén Pérez Mies, Sara Corral Moreno, Sonia Rivas Fidalgo, Jacobo Cabañas Montero\",\"doi\":\"10.3233/BD-220056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Metastases from extramammary malignant neoplasms are very rare, accounting for less than 2% of all breast malignancies.</p><p><strong>Objective: </strong>The aim of this study is to describe the clinicopathological features and prognosis of breast metastases from non-primary breast malignancies at our institution.</p><p><strong>Methods: </strong>We performed a retrospective observational study, obtaining data from electronic medical records and pathology databases between January 1985 and December 2020 for patients diagnosed with breast metastasis from non-primary breast malignancies. Only patients diagnosed by biopsy were included.</p><p><strong>Results: </strong>Fifteen patients diagnosed with breast metastases from non-primary breast malignancies were included, 13 women (86,67%) and 2 men (13,33%). The median age at time of initial diagnosis was 56 years (IQR 21-68). The most frequent primary malignancy was melanoma (9/15; 60%). The median time to diagnosis of breast metastases was 65 months (IQR 13-106). The most common diagnostic modality was CT-scan (10/15; 66,67%). The median follow-up was 96 months (IQR 29-136). Eight patients underwent surgery (53,3%), being the most common surgical intervention breast-conserving surgery (5/8; 62,5%). Mortality at the end of follow-up was 53,3% (8/15). On the survival analysis, we found no differences between patients undergoing surgery and those only receiving systemic treatment [41,5 months (IQR 17,5-57,5) versus 14 months (IQR 2-24), respectively; p = 0,161].</p><p><strong>Conclusions: </strong>Breast metastases from non-primary breast malignancies are extremely rare and represent a diagnostic and therapeutic challenge, due to the poor prognosis of these patients. Thus, arriving at the correct diagnosis is crucial to avoid unnecessary treatment in this population.</p>\",\"PeriodicalId\":9224,\"journal\":{\"name\":\"Breast disease\",\"volume\":\"42 1\",\"pages\":\"223-228\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/BD-220056\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:乳腺外恶性肿瘤的转移非常罕见,占所有乳腺恶性肿瘤的不到2%。目的:本研究旨在描述我院非原发性乳腺恶性肿瘤乳腺转移的临床病理特征和预后。方法:我们进行了一项回顾性观察性研究,从1985年1月至2020年12月期间的电子医疗记录和病理学数据库中获得了非原发性乳腺恶性肿瘤乳腺转移患者的数据。仅包括经活检诊断的患者。结果:15名被诊断为非原发性乳腺恶性肿瘤乳腺转移的患者包括在内,13名女性(86,67%)和2名男性(13,33%)。初次诊断时的中位年龄为56岁(IQR 21-68)。最常见的原发性恶性肿瘤是黑色素瘤(9/15;60%)。乳腺转移瘤的中位诊断时间为65个月(IQR 13-106)。最常见的诊断方式是CT扫描(10/15;66,67%)。中位随访时间为96个月(IQR 29-136)。8名患者接受了手术(53.3%),是最常见的保乳手术(5/8;62.5%)。随访结束时的死亡率为53.3%(8/15)。在生存率分析中,我们发现接受手术的患者和仅接受全身治疗的患者之间没有差异[41.5个月(IQR 17,5-57,5)和14个月(IQ R 2-24);p=0161]。结论:非原发性乳腺恶性肿瘤的乳腺转移极为罕见,由于这些患者的预后不佳,这是一个诊断和治疗挑战。因此,得出正确的诊断对于避免对这一人群进行不必要的治疗至关重要。
Breast metastases from non-primary breast malignancies: What should we know?
Background: Metastases from extramammary malignant neoplasms are very rare, accounting for less than 2% of all breast malignancies.
Objective: The aim of this study is to describe the clinicopathological features and prognosis of breast metastases from non-primary breast malignancies at our institution.
Methods: We performed a retrospective observational study, obtaining data from electronic medical records and pathology databases between January 1985 and December 2020 for patients diagnosed with breast metastasis from non-primary breast malignancies. Only patients diagnosed by biopsy were included.
Results: Fifteen patients diagnosed with breast metastases from non-primary breast malignancies were included, 13 women (86,67%) and 2 men (13,33%). The median age at time of initial diagnosis was 56 years (IQR 21-68). The most frequent primary malignancy was melanoma (9/15; 60%). The median time to diagnosis of breast metastases was 65 months (IQR 13-106). The most common diagnostic modality was CT-scan (10/15; 66,67%). The median follow-up was 96 months (IQR 29-136). Eight patients underwent surgery (53,3%), being the most common surgical intervention breast-conserving surgery (5/8; 62,5%). Mortality at the end of follow-up was 53,3% (8/15). On the survival analysis, we found no differences between patients undergoing surgery and those only receiving systemic treatment [41,5 months (IQR 17,5-57,5) versus 14 months (IQR 2-24), respectively; p = 0,161].
Conclusions: Breast metastases from non-primary breast malignancies are extremely rare and represent a diagnostic and therapeutic challenge, due to the poor prognosis of these patients. Thus, arriving at the correct diagnosis is crucial to avoid unnecessary treatment in this population.
期刊介绍:
The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.